Publication: Regulatory Oversight, Causal Inference, and Safe and Effective Health Care Machine Learning
Loading...
Open/View Files
Date
2020-04
Authors
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Oxford University Press (OUP)
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Stern, Ariel Dora, and W. Nicholson Price, II. "Regulatory Oversight, Causal Inference, and Safe and Effective Health Care Machine Learning." Biostatistics 21, no. 2 (April 2020): 363–367.
Abstract
In recent years, the applications of Machine Learning (ML) in the health care delivery setting have grown to become both abundant and compelling. Regulators have taken notice of these developments and the U.S. Food and Drug Administration (FDA) has been engaging actively in thinking about how best to facilitate safe and effective use. Although the scope of its oversight for software-driven products is limited, if FDA takes the lead in promoting and facilitating appropriate applications of causal inference as a part of ML development, that leadership is likely to have implications well beyond regulated products.
Description
Other Available Sources
Research Data
Keywords
Statistics, Probability and Uncertainty, General Medicine, Statistics and Probability
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service